吸入抗结核药物治疗肺结核的研究进展  

Research progress of inhaled anti-tuberculous drugs in the treatment of pulmonary tuberculosis

作　　者：叶静[1] 于洪志[1] 邵红霞[1] 武俊平[1] YE Jing;YU Hongzhi;SHAO Hongxia;WU Junping(Department of Tuberculosis,Haihe Hospital,Tianjin University,China Key Research Laboratory for Infectious Disease Prevention for State Administration of Traditional Chinese Medicine,Tianjin 300350,China)

机构地区：[1]天津市海河医院,天津大学海河医院结核科,国家中医药管理局传染病重点研究室,300350

出　　处：《天津医药》2022年第9期998-1001,共4页Tianjin Medical Journal

基　　金：2021年度天津市科技计划项目(20JCYBJC01250);2019年度天津市津南区科技计划项目(20200112)。

摘　　要：吸入抗结核药物治疗支气管结核已取得较好的效果。但雾化药物微粒直径过大,药物分布不均匀使其不能用于肺组织结核的患者。近年随着药物载体研究的深入,以吸入的方式到达肺组织的剂型不断被成功研发,其具有良好的安全性和有效性。该文就吸入抗结核药物治疗肺组织结核的研究进展进行综述。Inhalation of antituberculous drugs in the treatment of pulmonary tuberculosis has achieved good results in patients with bronchial tuberculosis.However,the diameter of atomized drug particles is too large and the drug distribution is uneven,so that it can not be used for patients with alveolar tissue tuberculosis.In recent years,with the in-depth development of follow-up drug carriers,it is possible to apply antituberculous drugs to patients with alveolar tissue tuberculosis by inhalation,which have good safety and effectiveness.This paper reviews the research progress of inhaled antituberculous drugs in the treatment of alveolar tissue tuberculosis.

关 键 词：结核 肺 抗结核药 吸入 载药技术 

分 类 号：R446.5[医药卫生—诊断学]